HCW Biologics Inc.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunotherapies. The company's core mission is to extend human healthspan by addressing chronic, low-grade inflammation, often referred to as "inflammaging," which is implicated in various age-related diseases. Headquartered in Miramar, Florida, HCW Biologics was founded by Dr. Hing C. Wong, who also serves as its Chief Executive Officer.

The company's pipeline is built upon proprietary platform technologies, including the "Tissue Factories" (TOBI) and the T-cell Receptor Beta Chain constant region (TRBC) platforms, which are used to create multi-functional fusion immunotherapeutics. Key product candidates include HCW9218, a bifunctional immunotherapeutic in clinical trials for solid tumors and pancreatic cancer, and HCW9302, an IL-2 fusion protein complex undergoing Phase 1 trials for autoimmune and proinflammatory conditions such as alopecia areata. HCW Biologics also develops other candidates like HCW9201, HCW9206, HCW11-006, and the T-cell engager HCW11-018b, targeting market segments such as oncology, autoimmune diseases, and various age-related conditions.

Recent notable developments for HCW Biologics include the advancement of its T-cell engager program, HCW11-018b, with preclinical data demonstrating tumor shrinkage and metastasis prevention, and an Investigational New Drug (IND) filing projected for the first half of 2027 for pancreatic and ovarian cancer. The company also secured an exclusive worldwide license for HCW11-006 with Beijing Trimmune Biotech Co., Ltd., which included a $7.0 million upfront payment. HCW Biologics regained compliance with Nasdaq listing rules in February 2026 and reported its fourth quarter and fiscal year 2025 business highlights and financial results in March 2026.